RAF1 and hereditary clear cell renal cell carcinoma: One of these multikinase inhibitors (MKIs), sorafenib, was originally intended to treat advanced renal cell carcinoma and hepatocellular carcinoma patients by blocking the serine threonine kinase RAF-1 in the RAF/MEK/ERK signalling cascade.